Pharming Group (NASDAQ:PHAR) Shares Gap Up – Still a Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) gapped up before the market opened on Friday . The stock had previously closed at $13.86, but opened at $14.68. Pharming Group shares last traded at $14.72, with a volume of 3,915 shares trading hands.

Pharming Group Stock Up 7.4%

The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.02 billion, a P/E ratio of -114.46 and a beta of 0.05. The company has a 50-day moving average of $12.50 and a two-hundred day moving average of $10.56.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The company had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.